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Abstract
Background: Patients with rheumatoid arthritis (RA) in clinical remission may have ultrasound-defined synovitis
according to the presence of power Doppler (PD) signal. The objective was to describe the immunopathologic
characteristics of ultrasound-defined synovitis compared with synovitis in patients with clinically active RA.
Methods: We included between 6 and 8 ultrasound-guided synovial biopsies per patient from 20 patients with RA
in clinical remission (DAS28-ESR <2.6) with PD signal, 22 synovial tissue samples (ST) from patients with clinically
active RA (swollen joint with confirmed inflammatory synovial fluid) as inflammatory controls, and 10 ST from
non-inflammatory controls. Immunostaining for CD3 (T lymphocytes), CD20 (B lymphocytes), CD68 (macrophages),
CD117 (mast cells), hsp47 (fibroblasts), bFGF and CXCL12 (angiogenic factors) was made and quantified by digital
image analysis. The number of CD31 vessels/mm2 was quantified.
Results: RA patients in remission with PD signal had significantly reduced synovial T-cell, B-cell, mast cell and
fibroblast density, but similar macrophage infiltration compared with patients with clinically active RA. Vascularity,
bFGF and CXCL12 were partially reduced in RA patients in remission with PD signal compared to those with active
RA, but were significantly higher compared with ST from non-inflammatory controls. During the 12-month follow
up, 8/20 RA patients (40 %) lost remission: all had synovial hypertrophy grade ≥2 and significantly more synovial B
cells and mast cells than patients maintaining remission.
Conclusions: Asymptomatic ultrasound-defined synovitis and clinically active arthritis differ in the degree of
infiltrating lymphoid, mast cells and fibroblast density, but are similar with respect to macrophage infiltration.
Persistently increased angiogenic factor expression and vascularity may explain the persistence of a PD signal.
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Background
Early treatment, the availability of biologic therapies and
treat-to-target strategies has made remission a realistic
goal in rheumatoid arthritis (RA) [1–5]. However, signifi-
cant numbers of RA patients classified as being in clinical
remission have detectable synovitis on ultrasound (US) or
magnetic resonance imaging (MRI) [6–10]. These patients
have an increased probability of reactivation of RA and/or
radiological progression during follow up. The persistence
of subclinical synovitis, as evaluated by power Doppler
(PD) US has been associated with a high risk of flares and
joint damage [11–14]. Understanding the immunopathol-
ogy underlying US-defined synovitis in RA patients in
remission may increase knowledge of the physiopathology
of RA and identify potential biological biomarkers of
further reactivation and the progression of structural
damage.
Studies suggest that PD scores correlate with vascular
and inflammatory cell infiltration [15, 16]. However, in
RA patients in clinical remission, only retrospective,
limited semiquantitative pathological data obtained from
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the joints of patients undergoing replacement surgery
have been reported [17]. To identify the pathological
basis of these findings, we aimed to analyze the
immunopathologic characteristics of synovial tissue (ST)
obtained from RA patients in clinical remission with
US- defined synovitis (presence of PD signal) and to de-
termine whether immunopathologic changes predict the




Consecutive patients with RA were selected, who had
been in clinical remission for ≥6 months and had PD
signal. Patients had a 28-joint Disease Activity Score
(DAS28) <2.6 and no swollen or tender joints as
evaluated by two independent rheumatologists in the
RA outpatient clinic. Patients aged <18 years, with
allergy to local anesthetics, anticoagulant treatment, or
unhealthy skin at the site of interest, were excluded.
Clinical and US examinations were performed at the
outpatient clinic of the rheumatology service and the
US-guided synovial biopsy was carried out within 24 h
of the clinical and US examination. We obtained biop-
sies from 24 patients, but 4 of the biopsies were non-
evaluable due to a lack of a well-defined synovial lining.
Finally, 20 patients with suitable synovial samples were
clinically followed for 12 months to detect relapse from
remission. All 20 patients completed the follow up.
We also included ST from two control groups: (1) syn-
ovial biopsies from unselected patients with clinically
active RA (n = 22), and (2) non-inflammatory ST (control)
obtained on arthroscopic surgery from 10 selected pa-
tients (60 % male; mean age (± SD) 42 (±8) years), who
had meniscal lesions, but had no osteoarthritic or inflam-
matory lesions on MRI and had histologically normal ST.
The study was approved by the Ethics Committee of the
Hospital Clinic of Barcelona (Comité Ético de Investigación
Científica del Hospital Clínic de Barcelona, Spain
(2011/6490)) and signed informed consent was ob-
tained from each patient.
US assessment and US-guided synovial biopsy
All US assessments were performed using high-
sensitivity US equipment (Acuson Antares®, Siemens
AG, Erlangen, Germany), using a frequency range from
10 to 12 MHz and pulse repetition frequency between
500 and 800 Hz. Receiver gain settings were controlled
to eliminate the appearance of artifacts. Joint US
findings were characterized according to published
Outcome Measures in Rheumatology (OMERACT) defi-
nitions [18]. An experienced sonographer (JR), blinded
to the results of the clinical joint examination, evaluated
both knees and 11 joints in each hand (including
proximal interphalangeal joints, metacarpophalangeal
joints (MCP) and wrists) for synovial hypertrophy (SH)
and intra-articular PD signal according to European League
Against Rheumatism (EULAR) guidelines [19]. SH and PD
scores were independently quantified (grades 0–3). US-
defined synovitis was based on the presence of PD signal.
Intra-rater agreement was calculated as previously de-
scribed [20], and was 0.81 for SH and 0.92 for PD.
US-guided synovial biopsies were performed using the
same US equipment. Two operators (JDC and JR) per-
formed all biopsies. Only joints with PD signal were se-
lected for biopsy. Biopsies were carried out in an
operating theatre and six to eight synovial biopsies were
taken per procedure. Each US biopsy was made accord-
ing to the technique described by Kelly et al. [21]. There
were no complications after the procedures.
Histological and immunohistochemical assessments
ST were routinely fixed and embedded in paraffin.
Deparaffinized sections were cooked to perform anti-
gen retrieval when required. Slides were subsequently
stained with an automated immunostainer (TechMate
500 Plus; Dako, Cambridge, UK) using the following
monoclonal antibodies: anti-CD3 (clone PS1; Novocastra,
Newcastle, UK) for T-lymphocytes, anti-CD20 (clone L26;
Dako) for B-lymphocytes, anti-CD68 (clone KP-1; Dako)
for CD68 +macrophages, anti-CD117 (rabbit anti-human
polyclonal antibody; Dako) for mast cells, anti-Hsp47
monoclonal antibodies (IgG2b M16.10A1 clone; Assay
Designs) for synovial fibroblasts, anti-CD31 (clone JC70A;
Dako) for endothelial cells, and anti-basic fibroblast
growth factor (bFGF) (polyclonal SC-79, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-CXCL12
(clone K15C [22]) for angiogenic markers, which were
significantly increased in serum from these patients in our
previous study [20]. As a negative control, the primary
antibodies were substituted by isotype-matched and
concentration-matched control antibodies. The primary
antibodies were subsequently detected by an avidin-
biotin-peroxidase-based method (Envision System; Dako)
and an aminoethylcarbazole color reaction (Sigma-
Aldrich, St. Louis, MO, USA) as previously described [23].
Finally, the slides were counterstained with hematoxylin.
Digital image analysis
Stained slides were scored on digital image analysis by
an independent observer (RC), who was blinded to the
diagnosis and the clinical data. Only slides with well-
defined lining and sub-lining areas were included. Each
stained slide was scored in its entirety by dividing it into
different regions. Within each region, the number of
stained cells per area and the percentage of stained cells
were measured in at least 20 high-power fields using the
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AnalySIS®Imaging processing program (Olympus®) as
previously described [24].
Statistical analysis
Quantitative immunohistologic data were analyzed using
the nonparametric Mann–Whitney test or the Kruskal-
Wallis test with the post-hoc Dunn test where appro-
priate. Correlation between variables was analyzed using
Spearman’s test. Values of p < 0.05 were considered sig-
nificant. The statistical analyses were carried out using
SPSS V.18 software.
Results
Clinical, demographic and US data
ST samples from 20 patients with RA in remission, who
had a PD signal, 22 ST samples from RA patients with
active synovitis (swollen and tender joint with inflamma-
tory synovial fluid), and 10 ST samples from non-
inflammatory controls were included. The clinical and
demographic data for the RA patients are shown in
Table 1. In both the active RA and remission RA groups,
the joint with greatest disease activity as assessed by US
was selected for biopsy. This means there was the high-
est grade of PD signal and the highest grade of SH in
joints with a similar grade of PD signal. Most biopsies in
the remission group were taken from the wrist and
MCP, the joints that were involved more frequently.
Biopsies in the active group were mostly taken from the
knee due to the additional therapeutic effect of the
arthroscopic lavage.
Patients with active disease had longer disease dur-
ation and, as expected, higher DAS28 and greater use of
prednisone compared with patients in remission, who
had a PD signal (Table 1). No significant differences in
the percentages patients on DMARDs or biologic
therapy were found between the active RA and remis-
sion RA groups. The duration of clinical remission was
37 (8–58) months (median (IQR)).
Of the 20 patients in remission, who had PD signal, 16
(80 %) also had SH grade ≥2, fulfilling a previously reported
more stringent criterion of synovitis (SH grade ≥ grade 2
plus a PD signal). This definition is based on the concept
that synovitis is the presence of synovial villae (hyper-
trophy) with active vessels (PD signal) and identifies a
subgroup of RA patients in clinical remission with signifi-
cantly greater disease activity and higher serum levels of
angiogenic cytokines [20]. All RA patients with clinically
active disease had SH grade ≥2 and a moderate-to-severe
signal (PD ≥2), whereas 85 % of RA patients in clinical
remission had a mild PD signal (PD = 1) and 15 % had a
PD signal = 2 (Table 1).
Immunopathologic characterization of RA patients in
clinical remission
We first analyzed potential differences in the density of
inflammatory cell infiltration between ST from RA pa-
tients in remission, who had PD signal, and patients with
clinically active RA. ST from patients in remission, who
had PD signal, had significantly reduced density of CD3+
T lymphocytes (p = 0.0001), CD20+ B lymphocytes (p =
0.0001) and CD117+ mast cells (p = 0.0002) compared
with patients with clinically active RA. No significant
differences in the density of total, lining, or sub-lining
CD68+ macrophages were found between patients with
clinically active RA and those in remission (Fig. 1).
As vascular and stromal changes have been suggested
to explain the persistence of subclinical inflammation,
we analyzed these changes in ST from the three study
groups. Patients in remission, who had a PD signal, had
significantly reduced density of CD31+ blood vessels
compared with patients with active RA (p = 0.04), but
had significantly increased density compared with non-
inflammatory ST samples from controls (p = 0.02). The
density of hsp47+ fibroblastic cells was significantly re-
duced in RA patients in remission who had a PD signal
compared to patients with active RA (p = 0.002) and was
Table 1 Clinical and demographic data for patients with
rheumatoid arthritis (RA)
Active RA (n = 22) Remission RA (n = 20) P value
Female, n (%) 16 (72.7) 15 (75) 0.867
Age, years,
mean (SD)
58.8 (9.6) 53.7 (10.8) 0.346
Disease duration,
years, mean (SD)
12.5 (9.8) 8.5 (8.2) 0.001
Rheumatoid factor+,
n (%)
14 (63.6) 11 (55) 0.569
ACPA+, n (%) 15 (68.1) 18 (90) 0.085
DAS28-ESR,
mean (SD)
5.41 (1.30) 1.92 (0.32) 0.001
Biological therapy,
n (%)
14 (63.6) 10 (50) 0.231
Prednisone, n (%) 18 (81.8) 2 (10) 0.0001
DMARDs, n (%) 20 (90.9) 16 (80) 0.881
Biopsy location
MCP, n (%) 0 (0) 3(15)
Wrist, n (%) 4 (18.1) 13 (65)
Knee, n (%) 18 (81.8) 4 (20)
PD, n (%) 22 (100) 20 (100)
PD ≥2, n (%) 22(100) 3 (15)
SH ≥2, n (%) 22 (100) 16 (80)
SH ≥2 + PD, n (%) 22 (100) 16 (80)
SD standard deviation, ACPA anti-cyclic citrullinated peptide/protein antibody,
DAS28 28-joint Disease Activity Score, ESR erythrocyte sedimentation rate,
DMARD disease-modifying antirheumatic drug, MCP metacarpophalangeal
joint, PD power Doppler, SH synovial hypertrophy
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similar to that in controls with no inflammatory disease
(Fig. 2).
We also analyzed the expression of bFGF and CXC12,
two angiogenic factors that we previously found to be
increased in serum from RA patients in remission, who
had PD signal, [20]. The expression of CXCL12 was
significantly increased in patients with clinically active
RA compared with those in remission, but CXCL12
expression in the remission group was still significantly
higher than in the control group who did not have
inflammatory disease (Fig. 2). In contrast, the expression
of bFGF in the remission group did not significantly
differ from that in the group clinically active RA, but
was significantly higher than in the non-inflammatory
control group (Fig. 2).
High risk of flare in patients with RA in remission who
had power Doppler signal and synovial hypertrophy ≥2
All patients in remission, who had PD signal, were
followed for 12 months, during which 8 (40 %) came out
of remission, all of whom met a more stringent criterion
for US synovitis (PD signal plus SH grade ≥2) on biopsy.
These patients had a significantly higher density of
CD20+ B cells (p = 0.009), CD117+ mast cells (p = 0.010),
and a non-significant trend towards higher density of
lining macrophages (p = 0.079) than patients maintaining
clinical remission (Table 2).
Discussion
To our knowledge, this is the first study to quantitatively
analyze changes in the infiltrating and resident cell com-
ponents that characterize RA patients in remission with
US-defined synovitis, based on the presence of PD signal.
Previous studies in active or end-stage joints in patients
with RA and osteoarthritis have shown correlation be-
tween US findings, mainly PD scores, and vascularity [15].
In a recent study of patients with clinically active RA there
was significant correlation between inflammatory cell in-
filtration (CD68 macrophages and CD3 T lymphocytes)
and vascularity with a PD color fraction [16].
Our results show that RA patients in clinical remission,
who have a persistent PD signal, have high macrophage
Fig. 1 Immunohistochemical analysis of inflammatory infiltrating cell populations in synovial tissues of rheumatoid arthritis (RA) patients in
remission, who had power Doppler signal, compared to patients with clinically active RA. The density of CD68 (macrophages) in the synovial
lining (L) and sub-lining (SL), CD3 (T lymphocytes), CD20 (B lymphocytes) and CD117 (mast cells), as assessed by quantitative digital image analysis
is shown. Data are represented as mean ± SD. NS not significant
Fig. 2 Immunohistochemical analysis of stromal and vascular cells, and expression of angiogenic factors in synovial tissues (ST) from rheumatoid
arthritis (RA) patients and non-inflammatory synovial tissues from controls (Normal ST). The density of of hsp47 (fibroblasts), CD31 (blood vessels),
and the expression of basic fibroblast growth factor (bFGF) and CXCL12, as assessed by quantitative digital image analysis is shown. Data are
represented as mean ± SD. NS not significant
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infiltration, comparable to patients with clinically active
RA, and increased vascularity. In contrast, lymphocytic and
mast cell infiltration and fibroblastic hyperplasia were sig-
nificantly reduced in these patients compared with patients
with clinically active disease. The comparison with ST from
individuals without inflammatory disease reinforces these
conclusions as there was increased vascularity but similar
fibroblastic density in RA patients in remission compared
with synovium from patients without inflammatory disease.
Furthermore, the expression of angiogenic factors, particu-
larly bFGF, which was found to be the best systemic bio-
marker of US synovitis in our previous study [20], was also
significantly elevated in the ST of these patients.
These results have implications for the mechanistic
understanding of US-defined synovitis in RA patients in
clinical remission. Synovial macrophage infiltration is
the best marker of active disease, and the most sensitive
to change after effective therapy [25, 26]. Therefore, the
finding of persistent macrophage infiltration suggests
that US synovitis does not differ physiopathologically
from clinically active synovitis. Despite the absence of
clinical signs (i.e., non-tender and non-swollen joints),
RA patients in remission, who have PD signal, would
appear to have a pathologic status whereby macrophage
depletion has not been achieved by therapy.
Our results also confirm the link between PD and in-
creased vascularity in these patients, as was previously
suggested to be characteristic of joints in clinically active
disease [15, 16]. The persistent expression of angiogenic
bFGF and macrophage infiltration provides a mechanis-
tic explanation for this pathologic observation. Interest-
ingly, bFGF-induced angiogenesis has been linked to
macrophage infiltration, underlining the pathogenic role
of this factor in RA [27, 28].
The main pathologic difference between clinical and
US-defined synovitis was in lymphocytes, mast cells and
fibroblasts, which were significantly-reduced in ST from
RA patients in remission who had PD signal. These cells
might, therefore, play a relevant role in the clinical ex-
pression of synovitis, but identification of the potential
mechanisms remains speculative. It is also interesting
that the levels of mast cell and B lymphocyte infiltration
were associated with clinical progression to symptom-
atic, clinically active RA during the follow up.
Mast cells play an essential role in some animal models
of arthritis [29] and are an important synovial reservoir of
pro-inflammatory cytokines, including TNFα and IL-17,
in RA [30, 31]. However, few studies have involved ana-
lysis of their changes or their prognostic implications in
patients on treatment [32]. Despite the significant reduc-
tion in asymptomatic US synovitis compared with clinical
synovitis, the levels in patients in remission correlated
with further clinical reactivation during follow up, sup-
porting a role for mast-cells in disease activity and in the
transition from subclinical to clinically active synovitis.
A higher density of synovial B lymphocytes was also
associated with RA reactivation. The efficacy of anti-
CD20 therapy in RA has shown the pathogenic
relevance of B cells, but the specific role of local synovial
B-cells is less clear [33]. An increased basal density of B
cells has been associated with a worse therapeutic re-
sponse to anti-CD20 but not to other therapies [34, 35].
Our study was limited by the relatively small sample
size. However, we were able to take synovial biopsies
from >80 % of eligible patients (meeting the PD signal
criteria). However, ST from the group with clinically
active RA was taken from joints with clinically active
disease (swollen joints with inflammatory synovial fluid)
and was included retrospectively to specifically compare
their immunopathologic characteristics with the RA
remission group. Therefore, the association between the
immunopathologic findings and disease reactivation are
only exploratory and require further confirmation. Fi-
nally, 80 % of patients with RA in remission, who had
PD signal, also had synovial hypertrophy grade ≥2, thus,
meeting a more stringent criterion for US synovitis [20].
These patients had a high risk of coming out of remis-
sion, as 50 % had arthritic flares during follow up.
Conclusions
This prospective study shows that the presence of US-
defined synovitis based on the presence of PD signal in
RA patients in clinical remission has a histopathological
correlate, which is characterized by an unbalanced re-
duction in the cellular components of clinically active
RA synovitis, with persistent macrophage and vascular
components. These results, together with our previous
observations on serum biomarkers [20], support a specific
cytokine profile in these patients, with the angiogenic
factor bFGF emerging as a potentially relevant mediator.
Table 2 Immunopathologic features of patients with rheumatoid






CD3/mm2 215.3 (258.1) 622.6 (1038.9) 0.232
CD20/mm2 25.7 (17.2) 276.3 (506.0) 0.009
CD31/mm2 53.8 (28.4) 54.6 (27.7) 0.953
CD68 total/mm2 1793.2 (2049.2) 4833.5 (4149.5) 0.329
CD68 lining/mm2 166.7 (254.7) 905.4 (877.4) 0.079
CD68 sub-lining/mm2 1500.8 (2036.2) 3927.9 (3343.9) 0.205
CD117/mm2 10.1 (8.9) 43.1 (27.6) 0.010
bFGF, % 4.5 (3.6) 7.2 (5.2) 0.217
Hsp47, % 91.1 (285.9) 134.4 (349.3) 0.247
Data are expressed as mean (SD). bFGF basic fibroblast growth factor,
Hsp47 heat shock protein 47
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